Venture capital investments in biopharma companies are on track this year to beat out 2017 and every year prior, although the projected amount raised and the number completed appear to be shy of the record-breaking year of 2018.

Venture capital investments in biopharma companies are on track this year to beat out 2017 and every year prior, although the projected amount raised and the number completed appear to be shy of the record-breaking year of 2018.

Biopharma companies priced four IPOs Thursday, the most for any single day since last June, raising a combined total of $303.9 million. When adding in Trevi Therapeutics Inc.'s $55 million IPO on Tuesday, the week's debuts represent a quarter of all those completed on U.S. exchanges this year, and about 18% of the total money raised.

Now that hepatitis C virus has many therapeutic options, biopharma companies have turned their attention to finding a potential cure – or at least a functional cure – for hepatitis B virus (HBV), targeting not only the reservoir virus but also finding ways to boost immunity, as they continually seek research funding.

Now that hepatitis C virus has many therapeutic options, biopharma companies have turned their attention to finding a potential cure – or at least a functional cure – for hepatitis B virus (HBV), targeting not only the reservoir virus but also finding ways to boost immunity, as they continually seek research funding.

Now that hepatitis C virus has many therapeutic options, biopharma companies have turned their attention to finding a potential cure – or at least a functional cure – for hepatitis B virus (HBV), targeting not only the reservoir virus but also finding ways to boost immunity, as they continually seek research funding.

VIENNA – Interim phase IIa data of hepatitis B core protein inhibitor ABI-H0731, from Assembly Biosciences Inc., used in combination with nucleos(t)ide (Nuc) analogues, indicate deep declines of hepatitis B virus (HBV) RNA and DNA to significantly low levels, suggesting potentially curative abilities.

VIENNA – Phase II data presented at The International Liver Congress on Saturday paved the way for Lille, France-based Genfit SA to move into another phase III trial sometime this year for its lead drug, elafibranor, this time for primary biliary cholangitis (PBC).

VIENNA – One year after reporting a 75% decrease in acute intermittent porphyria (AIP) attacks from a phase I trial of its RNAi drug, givosiran, Alnylam Pharmaceuticals Inc. returned to the International Liver Congress once again, this time announcing a 74% decrease in its much larger phase III Envision trial.